Kamada (KMDA) to Release Quarterly Earnings on Wednesday

Key Points

• Kamada is set to release its Q2 2025 earnings on August 13, with analysts expecting earnings of $0.09 per share and revenue of $158.59 million.
• The company's stock opened at $6.85 and has seen a 1-year price range between $5.17 and $9.15, reflecting its volatile performance.
• Institutional investors have recently increased their stakes in Kamada, with significant investments from firms like Goldman Sachs Group and Jane Street Group totaling over $1 million in new stakes.

Kamada (NASDAQ:KMDA - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect Kamada to post earnings of $0.09 per share and revenue of $158.59 million for the quarter. Kamada has set its FY 2025 guidance at EPS.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. The firm had revenue of $44.02 million during the quarter, compared to the consensus estimate of $154.06 million. Kamada had a net margin of 9.60% and a return on equity of 6.31%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Price Performance

Shares of KMDA stock traded up $0.16 on Wednesday, reaching $7.01. 39,125 shares of the company were exchanged, compared to its average volume of 53,180. The company has a 50-day moving average of $7.39 and a 200-day moving average of $7.05. The company has a market cap of $403.15 million, a price-to-earnings ratio of 24.17, a PEG ratio of 0.83 and a beta of 0.93. Kamada has a one year low of $5.17 and a one year high of $9.15.

Institutional Investors Weigh In On Kamada

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Kamada during the first quarter valued at about $582,000. Goldman Sachs Group Inc. bought a new position in shares of Kamada during the 1st quarter valued at approximately $497,000. NewEdge Advisors LLC increased its stake in shares of Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 28,165 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Kamada during the first quarter valued at $206,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on KMDA. Benchmark reissued a "buy" rating and issued a $15.00 price objective on shares of Kamada in a research note on Thursday, May 15th. Sidoti raised shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Kamada from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 21st.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.